Screener
Ultragenyx Pharmaceutical RARE Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Noncontrolling interest | 7 | 7 |
| Stockholders’ deficit: | ||
| Preferred stock, par value of $0.001 per share—25.0 shares authorized; nil outstanding in 2026 and in 2025 | — | — |
| Common stock, par value of $0.001 per share—250.0 shares authorized; outstanding—98.6 in 2026 and 96.6 in 2025 | — | — |
| Treasury stock, at cost, 0.3 shares in 2026 and 0.2 shares in 2025 | (10) | (8) |
| Deferred compensation obligation | 10 | 8 |
| Additional paid-in capital | 4,518 | 4,451 |
| Accumulated other comprehensive income | — | 1 |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's common stock?
- Ultragenyx Pharmaceutical (RARE) reported common stock of $0 in Q2 2026.
- How has Ultragenyx Pharmaceutical's common stock changed year-over-year?
- Ultragenyx Pharmaceutical's common stock decreased by 100.0% year-over-year, from $96K to $0.
- What is the long-term trend for Ultragenyx Pharmaceutical's common stock?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's common stock has grown at a -100.0% compound annual growth rate (CAGR), from $67K to $0.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Ultragenyx Pharmaceutical's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude